Join Drs Amelia Langston and Bijal Shah as they discuss CAR T-cell therapy for B-cell acute lymphoblastic leukemia, including clinical trials and real-world experience from their centers.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987067). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Cancer Immunotherapy With Chimeric Antigen Receptor (CAR) T Cells https://emedicine.medscape.com/article/2500108-overview

Acute Lymphoblastic Leukemia (ALL) Treatment & Management https://emedicine.medscape.com/article/207631-treatment#d15

Non-Hodgkin Lymphoma (NHL) https://emedicine.medscape.com/article/203399-overview

CD19 https://www.ncbi.nlm.nih.gov/gene/930

Tisagenlecleucel https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tisagenlecleucel

Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/29385370/

Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/32903253/

Blinatumomab (Rx) https://reference.medscape.com/drug/blincyto-blinatumomab-999984#10

FDA Approves Inotuzumab for Adults With B-Cell Acute Lymphoblastic Leukemia https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-inotuzumab-leukemia

Immune Effector Cell Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor-T Cell Therapy https://pubmed.ncbi.nlm.nih.gov/36081506/

Cytokine Release Syndrome https://emedicine.medscape.com/article/2500111-overview

Systemic Inflammatory Response Syndrome https://www.ncbi.nlm.nih.gov/books/NBK547669/

CD28 https://www.ncbi.nlm.nih.gov/gene/940

Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET) https://clinicaltrials.gov/ct2/show/NCT02535364

KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-label, Multicentre ZUMA-3 Study https://pubmed.ncbi.nlm.nih.gov/34097852/

CAR T-Cell Therapy Approved for Some Children and Young Adults With Leukemia https://www.cancer.gov/news-events/cancer-currents-blog/2017/tisagenlecleucel-fda-childhood-leukemia

Allogeneic Stem Cell Transplant https://www.cancer.gov/publications/dictionaries/cancer-terms/def/allogeneic-stem-cell-transplant

clonoSEQ Assay https://ous.clonoseq.com/for-clinicians/how-clonoseq-works/

Management of Hypogammaglobulinaemia and B-Cell Aplasia https://www.ncbi.nlm.nih.gov/books/NBK584138/

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse After Tisagenlecleucel in Children and Young Adults With Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/35019853/

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial https://pubmed.ncbi.nlm.nih.gov/36399695/

Therapeutic Targeting of Mutated p53 in Acute Lymphoblastic Leukemia https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939537/

MLL-Rearranged Acute Lymphoblastic Leukemia https://pubmed.ncbi.nlm.nih.gov/32350732/

Liposomal Vincristine for Relapsed or Refractory Ph-Negative Acute Lymphoblastic Leukemia: A Review of Literature https://pubmed.ncbi.nlm.nih.gov/24490021/

Consolidation Therapy With Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients With B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results From the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial https://ashpublications.org/blood/article/140/Supplement%202/LBA-1/493429/Consolidation-Therapy-with-Blinatumomab-Improves